Author: Kathryn Atkins

Figure 1: PET scan at screening (A), 5 months (B) and 8 months on treatment (C). CDK9 INHIBITORS

CDK9 Inhibitors: A Promising Combination Partner in Treating Hematological Malignancies

August 9, 2023

“[...] CDK9 inhibitors could play a role in future treatments of hematological diseases and could be a great ally when combined with other therapeutic approaches.” BUFFALO, NY- August 9, 2023… read more

Figure 1: Scheme of mechanisms of AGO2 (de)regulation and its (novel) functions in T-PLL.

Oncotarget

AGO2 in T-prolymphocytic Leukemia (T-PLL)

August 7, 2023

“For the first time, descriptive and mechanistic data implicated the involvement of molecules of the RNA interference (RNAi) machinery in T-PLL’s leukemogenesis [...]” BUFFALO, NY- August 7, 2023 – A… read more

Figure 2: Mechanism of radiation resistance in H3K27me3-deficient medulloblastoma.

Oncotarget

Epigenetically Guided Cancer Therapy: Targeting H3K27me3 Loss in Pediatric Brain Tumors

August 2, 2023

“[...] our discovery of H3K27me3 as an epigenetic marker of radiation resistance in medulloblastoma has a potential to open new therapeutic avenues [...]” BUFFALO, NY- August 2, 2023 – A… read more

Figure 1: Multi-clonal ER expression in DCIS.

Oncotarget

Multiclonality of Estrogen Receptor Expression in Ductal Carcinoma in Situ (DCIS)

August 1, 2023

“We have discussed in detail the clinical implications of ER in avoiding overtreatment and undertreatment in DCIS.” BUFFALO, NY- August 1, 2023 – A new editorial paper was published in… read more

Figure 2: ShRNAs targeting KIAA0930 decrease KIAA0930 mRNA expression and suppress muscle atrophy in PANC-1 cells in vitro.

Oncotarget

KIAA0930: A Cachexic Phenotype Inducer in Cancer Cells

July 26, 2023

“We believe that KIAA0930 would be a novel cachexia therapeutic target.” BUFFALO, NY- July 26, 2023 – A new research paper was published in Oncotarget's Volume 14 on July 20,… read more

Figure 1: Optimization of circulating tumor cells (CTC) staining and validation of p300 activity.

Oncotarget

A Multiplex Assay to Assess Activated p300/CBP in Circulating Prostate Tumor Cells

July 24, 2023

“The results from this initial cohort support the integration of these biomarkers into prospective clinical trials.” BUFFALO, NY- July 24, 2023 – A new research paper was published in Oncotarget's… read more

Figure 1: Combined targeting of SMO and BRD4 as a potential therapeutic strategy against melanoma.

Oncotarget

Novel Therapeutic Strategy Against Melanoma: Combined Targeting of Hedgehog Signaling and BRD4

July 19, 2023

“This evidence strengthens the relevance of the findings by Pietrobono et al., shedding light on the potential application of SMO inhibitors in concert with BRD4 inhibitors.” BUFFALO, NY- July 19,… read more

Figure 2: (A) Axial T2 MR shows a heterogeneous mass in the cardiophrenic space with evidence of anterior chest wall invasion and intercostal invasion. (B) Axial T2 MR shows 35 % of reduction in size of the synovial sarcoma mass in the cardiophrenic space.

Oncotarget

Case Report: Intrathoracic Synovial Sarcoma With BRAF V600E Mutation

July 18, 2023

“The prognosis of recurrent/metastatic SS remains poor, highlighting the need for a novel therapeutic strategy.” BUFFALO, NY- July 18, 2023 – A new case report was published in Oncotarget's Volume… read more

Oncotarget

Cetuximab’s Effectiveness and Toxicity in Advanced Cutaneous Squamous Cell Skin Cancer

July 12, 2023

“Our data demonstrate that cetuximab plus radiotherapy represents an active treatment option for laCSCC, with manageable toxicity.” BUFFALO, NY- July 12, 2023 – A new research paper was published in… read more

Figure 1: An integrated representation of the multifaceted effects of progesterone in breast cancer.

Oncotarget

Deciphering Progesterone’s Mechanisms of Action in Breast Cancer

July 10, 2023

“The mechanisms underlying the observed effects of progesterone on breast cancer outcomes are unclear.” BUFFALO, NY- July 10, 2023 – A new research perspective was published in Oncotarget's Volume 14… read more